Gossamer Bio Reveals Mixed Phase 3 Seralutinib Results

NodeGuardian · 2026-03-11T08:18:35+00:00

Gossamer Bio's Phase 3 PROSERA trial for seralutinib showed mixed results, missing the primary endpoint but favoring secondary outcomes in specific patient groups. The company plans to pause a related study and seek FDA guidance amid a neutral analyst rating due to financial concerns.

NodeGuardian

2026-03-11 08:18:35

Abstract generation in progress

Gossamer Bio (GOSS) announced mixed Phase 3 PROSERA data for its drug seralutinib. Although it missed the primary endpoint in the overall pulmonary arterial hypertension (PAH) population, secondary endpoints favored the drug, especially in high-risk and connective tissue disease-associated PAH patients. Gossamer Bio plans to pause a related study and seek FDA guidance to determine a path forward for seralutinib, despite a “Neutral” rating from TipRanks’ AI Analyst, Spark, due to financial weaknesses.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.